Soleno Therapeutics (SLNO) Assets Average (2014 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Assets Average data on file, last reported at $586.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $586.1 million, up 80.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $586.1 million (up 80.6% YoY), and the FY2025 annual result was $447.4 million, up 74.88% from the prior year.
• Assets Average improved to $586.1 million in Q1 2026 per SLNO's latest filing, from $581.9 million in the prior quarter.
• Over five years, Assets Average peaked at $586.1 million in Q1 2026 and troughed at $23.0 million in Q1 2023.
• A 5-year average of $215.8 million and a median of $174.8 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average slumped 41.06% in 2023, then surged 836.96% in 2024.
• A 5-year view of Assets Average shows it stood at $29.2 million in 2022, then soared by 317.67% to $122.1 million in 2023, then surged by 156.99% to $313.8 million in 2024, then surged by 85.4% to $581.9 million in 2025, then advanced by 0.73% to $586.1 million in 2026.
• Business Quant data shows SLNO's Assets Average at $586.1 million in Q1 2026, $581.9 million in Q4 2025, and $466.1 million in Q3 2025.